Atrium Therapeutics Executive Compensation (FY24)
RNA · Executive and director compensation, fiscal 2022 to 2024
The paid brief on Atrium Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 12, 2026Latest filing (8-K): June 10, 2025
5 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
254 figures on this page: 250 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
More on Atrium Therapeutics
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Sarah Boyce: $11,139,719 → $14,176,480 (27.3% higher)
Say-on-pay support: 98.5% → 76.1% (22.4 points lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Atrium Therapeutics' chief executive and what were they paid?
Sarah Boyce, President and Chief Executive Officer, received $14,176,480 in total compensation for fiscal 2024. Boyce's total was 27.3% higher than the $11,139,719 reported for fiscal 2023.
What was Atrium Therapeutics' say-on-pay result?
The say-on-pay proposal drew 76.1% of votes cast for or against in favor at the meeting held June 10, 2025 for fiscal 2024.
Which companies are in Atrium Therapeutics' peer group?
Companies named in the disclosed peer group include Arcturus Therapeutics Holdings, Beam Therapeutics, Crinetics Pharmaceuticals, Dyne Therapeutics and Erasca, among others.
What is Atrium Therapeutics' chief executive pay ratio?
The company reported a chief executive pay ratio of 48:1 for fiscal 2024.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Sarah Boyce President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Teresa McCarthy Chief Human Resources Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
W. Michael Flanagan Chief Scientific Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Michael MacLean Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Sarah Boyce President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
W. Michael Flanagan Chief Scientific Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Michael MacLean Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Teresa McCarthy Chief Human Resources Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Sarah Boyce President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
John Moriarty Chief Legal Officer and Corporate Secretary | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Michael MacLean Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
W. Michael Flanagan Chief Scientific Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Teresa McCarthy Chief Human Resources Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| John B. Moriarty Jr | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| John B. Moriarty Jr | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| John B. Moriarty Jr | PSU | ◇ | — | — | ◇ | — | — | ◇ |
| Michael F. MacLean | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Michael F. MacLean | PSU | ◇ | — | — | ◇ | — | — | ◇ |
| Michael F. MacLean | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Sarah Boyce | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Sarah Boyce | PSU | ◇ | — | — | ◇ | — | — | ◇ |
| Sarah Boyce | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Teresa McCarthy | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Teresa McCarthy | PSU | ◇ | — | — | ◇ | — | — | ◇ |
| Teresa McCarthy | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| W. Michael Flanagan | PSU | ◇ | — | — | ◇ | — | — | ◇ |
| W. Michael Flanagan | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| W. Michael Flanagan | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Teresa McCarthy | Option | ◇ | — | ◇ | 1/20/2033 |
| Option | ◇ | — | ◇ | 1/20/2034 | |
| Option | ◇ | — | ◇ | 2/2/2031 | |
| Option | ◇ | — | ◇ | 1/21/2032 | |
| Option | ◇ | — | ◇ | 9/11/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| John Moriarty | Option | ◇ | — | ◇ | 8/1/2034 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| W. Michael Flanagan | Option | ◇ | — | ◇ | 1/20/2034 |
| Option | ◇ | — | ◇ | 1/21/2032 | |
| Option | ◇ | — | ◇ | 9/11/2033 | |
| Option | ◇ | — | ◇ | 1/21/2031 | |
| Option | ◇ | — | ◇ | 1/20/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Michael MacLean | Option | ◇ | — | ◇ | 9/11/2033 |
| Option | ◇ | — | ◇ | 1/20/2033 | |
| Option | ◇ | — | ◇ | 1/20/2034 | |
| Option | ◇ | — | ◇ | 1/21/2032 | |
| Option | ◇ | — | ◇ | 2/2/2031 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Sarah Boyce | Option | ◇ | — | ◇ | 1/20/2034 |
| Option | ◇ | — | ◇ | 1/21/2032 | |
| Option | ◇ | — | ◇ | 9/11/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/20/2033 | |
| Option | ◇ | — | ◇ | 2/2/2031 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2024
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Simona Skerjanec | ◇ | — | ◇ | — | — | — | ◇ |
Troy Wilson, Ph.D., J.D | ◇ | — | ◇ | — | — | — | ◇ |
Noreen Henig | ◇ | — | ◇ | — | — | — | ◇ |
Noreen Henig, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Carsten Boess | ◇ | — | ◇ | — | — | — | ◇ |
Edward Kaye | ◇ | — | ◇ | — | — | — | ◇ |
Edward M. Kaye, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Tamar Thompson | ◇ | — | ◇ | — | — | — | ◇ |
Jean Kim | ◇ | — | ◇ | — | — | — | ◇ |
Arthur A. Levin, Ph.D and Sarah Boyce served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
- Arcturus Therapeutics Holdings ARCT
- Beam Therapeutics BEAM
- Crinetics Pharmaceuticals CRNX
- Dyne Therapeutics DYN
- Erasca ERAS
- IGM Biosciences IGMS
- Inhibrx Inc INBX
- Janux Therapeutics JANX
- Kymera Therapeutics KYMR
- Pliant Therapeutics PLRX
- RAPT Therapeutics RAPT
- Rocket Pharmaceuticals RCKT
- Stoke Therapeutics STOK
- Vaxcyte PCVX
- Ventyx Biosciences VTYX
- Verve Therapeutics VERV
- Zentalis Pharmaceuticals ZNTL
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2024 | June 10, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 13, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 15, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 15, 2022 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Atrium Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Atrium Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
254 figures on this page: 250 cited to the filing that reported them, 4 calculated from figures it prints.
250 cited to the filing
4 calculated from the filing
Documents cited
- 0001599901-25-000111Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001599901-25-000092CEO PAY RATIO · COMPENSATION TABLES · DIRECTOR COMPENSATION
- 0001599901-24-000085Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001599901-23-000035Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001193125-22-176510Item 5.07. Submission of Matters to a Vote of Security Holders.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Atrium Therapeutics executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/RNA (accessed 2026).
Short form: data: Velarion
The paid brief for Atrium Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
5 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Atrium Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Atrium Therapeutics discloses
The companies named in RNA's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}